About New Element Medicine
New Element Medicine is a company based in Zhenjiang (China) founded in 2012 by Shi Dongfang. New Element Medicine has raised $152.05 million across 5 funding rounds from investors including Livzon Pharmaceutical, Kaitai Capital and Fortune Capital Partners. New Element Medicine offers products and services including ABP-671 and ABP-745. New Element Medicine operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, NGM Biopharmaceuticals, Erasca and Revolution Medicines, among others.
- Headquarter Zhenjiang, China
- Founders Shi Dongfang
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Atom Therapeutics Co. Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$152.05 M (USD)
in 5 rounds
-
Latest Funding Round
$83 M (USD), Series D
Oct 16, 2023
-
Investors
Livzon Pharmaceutical
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of New Element Medicine
New Element Medicine offers a comprehensive portfolio of products and services, including ABP-671 and ABP-745.
Treats chronic gout and hyperuricemia through clinical trials.
Addresses acute gout with safety and efficacy in trials.
Funding Insights of New Element Medicine
New Element Medicine has successfully raised a total of $152.05M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $83 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in New Element Medicine
New Element Medicine has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Livzon Pharmaceutical, Kaitai Capital and Fortune Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Kaitai Capital is engaged in innovation investment management services.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for New Element Medicine
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by New Element Medicine
Investment portfolio details for New Element Medicine
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - New Element Medicine
Detailed financials for New Element Medicine
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
New Element Medicine Comparisons
Peer comparison for New Element Medicine
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of New Element Medicine
New Element Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, NGM Biopharmaceuticals, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Detailed competitors of New Element Medicine
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on New Element Medicine
Complete news archive for New Element Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about New Element Medicine
New Element Medicine was founded in 2012 and raised its 1st funding round 5 years after it was founded.
New Element Medicine is headquartered in Zhenjiang, China. It is registered at Zhenjiang, Jiangsu, China.
Shi Dongfang is the current CEO of New Element Medicine. They have also founded this company.
New Element Medicine is a funded company, having raised a total of $152.05M across 5 funding rounds to date.
Founded in 2012 and based in Zhenjiang, China, the company operates in the biotechnology sector. Focus is placed on developing pharmaceutical products for cancer and metabolic conditions. Pipeline includes URAT-1 targeting gout and hyperuricemia, as well as ABP-6061 and ABP-431 for non-alcoholic steatohepatitis, gastric cancer, colon cancer, and breast cancer. Operations center on research and drug development.
New Element Medicine's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
New Element Medicine offers ABP-671 and ABP-745.
New Element Medicine has 13 investors. Key investors include Livzon Pharmaceutical, Kaitai Capital, Fortune Capital Partners, Huajin Securities, and NNFE.